Skip Navigation

SANUWAVE joins MenaCare as Territory Sales Manager for Sourcing and Screening of Potential Partners and Access to Clinical Trial Participation in the Middle East

SUWANEE, GA - (NewMediaWire) - April 25, 2018 - SANUWAVE Health, Inc. (OTCQB: SNWV) is pleased to announce that the company will join MenaCare as the Territory Sales Manager for sourcing and screening of potential distributors and access to clinical trial participation for SANUWAVE’s products in the Middle East. The partnership with MenaCare will include a focus on screening and finalizing regional Joint Venture partner relationships.

Kevin Richardson ll, CEO of SANUWAVE, stated, “The decision to engage MenaCare was made to increase our focus and visibility within the Middle East. It is of the utmost importance that we partner with distributors that have influence and a good track record within the Middle East market. We also need speedy access to potential clinical trials to ensure we add value with our product offering as well as clinical proven outcomes. These factors will lead to faster market entry and closer ties with identified Key Opinion Leaders (KOL’s).” 

William Kaafarani, MenaCare’s CEO, stated, “MenaCare proved to be an ideal partner for SANUWAVE by providing regulatory and commercial support when introducing and expanding the company’s medical device portfolio in the Middle East.

“By partnering with MenaCare, SANUWAVE will have access to a multidisciplinary team with proven business acumen that will facilitate SANUWAVE's local market access efforts,” continued Mr. Kaafarani. “Our expertise in medical device commercialization, knowledge of the local market, and an extensive network of local contacts enable us to offer a wide range of services to forward-thinking companies like SANUWAVE. This partnership will allow SANUWAVE to successfully enter the market and achieve long-term growth in the Middle East.”

SANUWAVE is using this occasion to further educate on our lead wound care product dermaPACE®.  This Extracorporeal Shockwave Technology (ESWT) device, based upon electrohydraulic principles, is CE Marked and has enjoyed success in certain markets within the European Union treating a wide variety of skin conditions such as pressure ulcers, burns, post-operative wounds, and scar reduction. With the FDA approval, dermaPACE® has been proven, in US based clinical trials enrolling 336 subjects, to be safe and effective in the treatment of Diabetic Foot Ulcers.  Within a few weeks of initial treatment, wounds treated with dermaPACE® reduce in area at superior rates compared to control subjects. The dermaPACE® System exhibits superiority in wound area reduction within 12 weeks of initial treatment and exhibits superiority in wound closure within 20 weeks of initial treatment.  The use of dermaPACE® allows the clinician to more easily, and more cost-effectively, manage wounds.  More importantly, the patient’s quality of life improves significantly.  

For more information on SANUWAVE’s technology, please read our blog, “Shock This”, on our website at www.sanuwave.com.

About MenaCare
MenaCare is a full-service business consulting company focused on the delivery of innovative healthcare solutions. MenaCare specializes in planning and managing healthcare programs and projects throughout the Middle East. Through its alliance with several strategic business partners, MenaCare can assist international medical vendors, major manufacturers, hospitals, physician’s groups and government entities succeed in developing profitable ventures throughout the Middle East region.

Since its inception, MenaCare has delivered innovative solutions and services to many clients around the Middle East. MenaCare has adopted a no-nonsense approach to deliver superior quality services and easily implementable short and long-term strategies to achieve the desired objectives in the most efficient and cost-effective way. Our ability to deliver our commitment is rooted in our basic beliefs in partnership with low overhead and vast available resources offered to us from all over the world. We believe that all people are entitled and deserve to have access to the best affordable care possible.

About SANUWAVE Health, Inc. 
SANUWAVE Health, Inc. (OTCQB:SNWV) (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating System for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE® technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is US FDA cleared for the treatment of Diabetic Foot Ulcers.  The dermaPACE® System is also CE Marked throughout Europe and has license approval for the treatment of the skin and subcutaneous soft tissue in Canada, South Korea, Australia and New Zealand. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® System, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron®, Evotron® and orthoPACE® Systems in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food and industrial markets.

Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.

For additional information about the Company, visit www.sanuwave.com.

 

Contact: 

Millennium Park Capital LLC
Christopher Wynne
312-724-7845
cwynne@mparkcm.com

SANUWAVE Health, Inc.
Kevin Richardson II
Chairman of the Board
978-922-2447
investorrelations@sanuwave.com